What Sildenafil Teva Treats: Main Uses and Benefits

Sildenafil Teva is used across two distinct therapeutic domains where localized blood flow or pressure is compromised. The medication is primarily relevant for easing symptoms related to specific cardiovascular and sexual health conditions.

The medicine is commonly used to help with two primary indications: managing the functional symptoms of Pulmonary Arterial Hypertension (PAH), and addressing the symptomatic pattern of Erectile Dysfunction (ED). It is applied in situations where symptoms create noticeable physiological strain, such as shortness of breath or fatigue during physical activity, and for the functional inability to achieve or sustain sufficient penile stiffness. This therapeutic support assists with functional stability and contributes to easing the overall symptom load.

Restoring Functional Capacity and Managing Symptoms

For adult men with ED, the medication provides supportive relief when symptoms interfere with routine activities and is relevant for easing symptoms related to sexual health. In chronic conditions like PAH, the support is used in clinical settings that involve acute or unstable symptom patterns to provide support that helps ease the overall symptom burden.

---

Quick Fact: Relief for Vascular Strain Sildenafil Teva supports functional stability in conditions marked by heightened physiological stress on the circulatory system, helping to manage the strain placed on the cardiovascular network.

Regulatory References

1. NIH MedlinePlus Drug Information

Who can and cannot use Sildenafil Teva?

Sildenafil Teva is indicated for use only in adults (18 years and above). The official regulatory labeling strictly defines populations who are eligible and those who are formally contraindicated.

---

Absolute Contraindications

Use of this medicine is prohibited for patients who meet any of the following criteria:

• Concurrently taking nitrate medicines (e.g., nitroglycerin), nitric oxide donors, or guanylate cyclase stimulators (like riociguat).
• Recent history of stroke or myocardial infarction.
• Diagnosed with severe hypotension (resting blood pressure less than 90/50 mmHg).
• History of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) or severe hepatic impairment (Child-Pugh Class C).

Conditional Use and Restrictions

Certain populations require special consideration or a reduced starting dose:

• Patients with severe renal impairment (creatinine clearance <30 mL/min) or non-severe hepatic impairment.
• Individuals with anatomical penile deformation (e.g., Peyronie’s disease) or conditions predisposing to priapism (e.g., sickle cell anaemia).
• The medicine is not indicated for use in females (for the ED indication) and not recommended for pediatric patients with pulmonary hypertension.

The official interaction profile for Sildenafil Teva is determined by its effect on vascular tone and its hepatic clearance pathway. Co-administration of Sildenafil with specific agents is formally prohibited by regulatory authorities due to the risk of severe pharmacodynamic (PD) reinforcement.

Contraindicated Combinations

Strictly prohibited co-administration includes all forms of Nitric Oxide Donors (such as organic nitrates) and the Guanylate Cyclase Stimulator Riociguat. These combinations pose a documented hazard of severe hypotension. Concomitant use with other PDE5 inhibitors or other similar treatments is generally not recommended in regulatory labeling.

Pharmacokinetic and Exposure Interactions

Sildenafil is primarily cleared by the metabolic enzyme CYP3A4. Potent CYP3A4 inhibitors, including Ritonavir and Saquinavir, reduce Sildenafil clearance, leading to a significant pharmacokinetic interaction. This is documented to result in a substantial increase in systemic exposure, reaching up to an 11-fold increase in AUC. Conversely, agents that induce CYP3A4, such as Rifampin and St. John’s wort, are expected to decrease Sildenafil’s plasma concentration.

Pharmacodynamic Effects and Conditions

Additive PD effects are documented with agents that also lower blood pressure. Co-administration with Alpha-blockers (e.g., Doxazosin) and other Antihypertensive Agents may result in symptomatic hypotension. The greatest risk for this specific interaction is documented to occur within 4 hours post-Sildenafil dosing. The label notes that interaction risk is increased in patients with severe hepatic impairment.

Selective Targeting of the PDE5 Enzyme System

Sildenafil Teva functions as a selective competitive inhibitor of the enzyme Phosphodiesterase type 5 ( PDE5), which is crucial for regulating vascular smooth muscle tone. The mechanism focuses on blocking PDE5 from degrading the signaling molecule cyclic guanosine monophosphate ( cGMP). This molecular interaction ensures the cGMP signal persists, defining the critical first step in the drug's physiological influence.

---

Potentiating the Vasodilation Cascade

The action of preserving cGMP is integrated into the body's Nitric Oxide ( NO) signaling pathway. Sildenafil does not initiate the signal, but rather potentiates the natural NO response by stabilizing cGMP levels. This molecular accumulation activates Protein Kinase G ( PKG), which orchestrates a reduction in the concentration of intracellular calcium ions ( Ca^2+) within smooth muscle cells. The key physiological consequence of this cascade is the relaxation of vascular smooth muscle—a process known as vasodilation—resulting in increased localized blood flow.

---

️ Constraint of Mechanistic Selectivity

While selective for PDE5, the molecule also exhibits measurable inhibitory activity against Phosphodiesterase type 6 ( PDE6), an enzyme found in the retina. This molecular characteristic is a direct consequence of its structure and PDE6 activity in the retina.

How to Use Sildenafil Teva: Official Administration Guidelines

Sildenafil, the active ingredient in Sildenafil Teva, is administered through distinct, label-defined protocols based on the condition being addressed. The medicine is available as oral film-coated tablets (25 mg, 50 mg, 100 mg) for intermittent use and as a 20 mg tablet or 10 mg/mL oral suspension for sustained use.

---

Administration Protocols

Protocol	Use Pattern & Frequency	Standard Adult Dose (Initial)	Max Single Dose	Timing Constraints
Intermittent (e.g., ED)	As needed; maximum once per day	50 mg	100 mg	Taken 30 minutes to 4 hours before activity
Sustained (e.g., PAH)	3 times a day (TID)	20 mg TID	80 mg TID	Doses administered approximately 4 to 8 hours apart

---

Contextual and Population Adjustments

For the intermittent oral regimen, the following high-level adjustments should be considered at initiation:

• Lower Initial Dose: A starting dose of 25 mg is considered for patients with severe renal impairment (CLcr < 30 mL/min) or hepatic impairment (e.g., cirrhosis).
• Co-administration: When used with certain strong CYP3A4 inhibitors (e.g., ritonavir), the maximum single dose must not exceed 25 mg within 48 hours.

The medicine may be taken with or without food; however, consumption with a high-fat meal may delay the onset of activity. For the sustained (PAH) regimen, if a dose is missed, patients should take it as soon as remembered, but should not double the dose to compensate.

Sildenafil Teva: Recent Clinical Evidence

Sildenafil Teva is a generic version of sildenafil, meaning studies concerning its efficacy and safety profile are primarily derived from the comprehensive body of research on the reference medicine. Generic medications must demonstrate bioequivalence, ensuring the rate and extent of absorption into the bloodstream are comparable to the original product.

Core Research Areas

The most extensive clinical evidence for sildenafil (the active substance) focuses on two primary therapeutic areas:

• Erectile Dysfunction (ED): Large-scale, randomized, placebo-controlled trials have investigated the use of sildenafil in the broad population of men with ED. Studies consistently reported improved outcomes related to the ability to attain and maintain an erection sufficient for satisfactory sexual performance, with a successful intercourse attempt rate significantly higher than placebo in many trials. Efficacy was observed across various patient subgroups, including those with organic, psychogenic, and mixed etiologies, as well as men with co-morbidities like diabetes mellitus.
• Pulmonary Arterial Hypertension (PAH): Research supports its use in treating PAH to improve exercise capacity and delay clinical worsening in adults. Clinical trials, including double-blind, placebo-controlled studies, have shown that sildenafil helps reduce pulmonary vascular resistance, which is a key factor in the progression of the disease.

Safety and Long-Term Data

Clinical trials have also gathered extensive safety data. Common adverse events in trials typically included headache, flushing, and dyspepsia. Long-term studies, some extending up to three years, have explored the sustained outcomes and tolerability profile, noting that a small percentage of patients discontinued treatment due to insufficient response or adverse effects. The overall incidence of serious adverse events in the clinical trial database was found to be comparable between sildenafil and placebo.

Key Studies & References

1. SILDENAFIL tablet (for PAH), DailyMed Label

Common questions about Sildenafil Teva (FAQ)

---

Q: How long does the effect of Sildenafil Teva usually last?

A: Official product information does not specify the exact total duration of the clinical effect in terms of hours. However, the medicine's pharmacological properties, specifically its half-life (the time it takes for the amount of drug in the body to be cut in half), are what inform the authorized limits on dosing frequency.

---

Q: Can Sildenafil Teva be taken by people who don't have erection problems?

A: According to the regulatory prescribing information, this medicine is specifically indicated for the treatment of either erectile dysfunction (ED) or pulmonary arterial hypertension (PAH). The medicine is not authorized for use outside of its approved indications.

---

Q: Can taking Sildenafil Teva cause dependency?

A: Official documents from regulatory bodies do not classify Sildenafil as a controlled substance. Dependency, abuse, or addiction are not listed as known risks or reported adverse reactions associated with its use.

---

Q: What happens if I take Sildenafil Teva with alcohol?

A: Sildenafil has properties that relax blood vessels, and consuming it with alcohol may increase the risk of developing low blood pressure, known as hypotension. This effect can potentially lead to symptoms such as dizziness or lightheadedness, according to official information.

---

Q: Why do official documents mention not taking Sildenafil Teva with grapefruit juice?

A: Official product information states that grapefruit and grapefruit juice can significantly affect how your body processes Sildenafil. Grapefruit components can slow down the speed at which the medicine is broken down in the bloodstream, resulting in higher overall systemic exposure. These higher levels are associated with an increased potential for side effects.

---

Q: Does Sildenafil Teva affect fertility or sperm count?

A: Studies in animal models conducted prior to approval did not suggest that Sildenafil impairs fertility when used at therapeutic doses. Clinical studies performed on healthy male subjects also showed no significant changes in seminal parameters or sperm count.

---

Q: What are the signs of a serious allergic reaction to Sildenafil Teva?

A: Hypersensitivity reactions, which are another name for allergic reactions, are listed as a rare adverse event in the prescribing information. Official patient information describes that immediate medical attention is necessary if symptoms such as swelling of the face, lips, or throat, or difficulty breathing occur.

---

Q: Does taking Sildenafil Teva cause permanent changes to the body?

A: While the drug itself is not known to cause permanent structural or functional changes, official warnings highlight the risk of specific, rare adverse events that may result in permanent damage if not treated promptly. These events include Priapism (an erection lasting over four hours) and Non-arteritic anterior ischaemic optic neuropathy (NAION), which is a form of sudden vision loss.

---

Q: Why do official warnings mention speaking to a healthcare provider if chest pain occurs after use?

A: Regulatory patient counseling information indicates that if symptoms like chest pain, dizziness, or nausea occur during sexual activity after taking Sildenafil, the activity should be stopped, and medical assistance should be sought immediately. This instruction is due to the potential association of these symptoms with an underlying cardiovascular issue.

Storage and Disposal Instructions

Sildenafil Teva film-coated tablets do not require any special temperature storage conditions according to official regulatory labeling. The primary storage requirement is to keep the product in the original package to ensure it is protected from moisture and maintains its 3-year shelf-life.

Requirement	Official Statement
Temperature	No special temperature storage conditions are required.
Protection	Store in the original package to protect from moisture.
Child Safety	Keep out of the sight and reach of children.
Disposal	Dispose of any unused product or waste material in accordance with local requirements.

Disposal procedures must comply with the local guidelines established for medicinal waste management.